An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder

被引:0
|
作者
Castry, Mathieu [1 ]
Tin, Yjuliana [2 ]
Feder, Noah M. [3 ]
Lewis, Nikki [4 ]
Chatterjee, Avik [4 ,5 ]
Rudorf, Maria [4 ]
Samet, Jeffrey H. [4 ,5 ]
Beers, Donna [4 ]
Medley, Bethany [6 ]
Gilbert, Louisa [6 ]
Linas, Benjamin P. [1 ,5 ]
Barocas, Joshua A. [2 ]
机构
[1] Boston Med Ctr, Sect Infect Dis, Boston, MA USA
[2] Univ Colorado, Div Gen Internal Med & Infect Dis, Sch Med, 12631 E 17th Ave,Mailstop B180, Aurora, CO 80045 USA
[3] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[4] Boston Med Ctr, Sect Gen Internal Med, Boston, MA USA
[5] Boston Univ, Chobanian & Avedisian Sch Med, Boston, MA USA
[6] Columbia Univ, Sch Social Work, Social Intervent Grp, New York, NY USA
来源
JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT | 2024年 / 167卷
基金
美国国家卫生研究院;
关键词
Mobile health units; Opioid use disorder; Harm reduction; Medications for opioid use disorder; Economic evaluation; OVERDOSE; MASSACHUSETTS; BUPRENORPHINE; PROGRAM; IMPACT; STATES;
D O I
10.1016/j.josat.2024.209517
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background & objective: Mobile substance use treatment units are effective approaches to increase treatment access and reduce barriers to opioid use disorder (OUD) care. However, little is known about the economic costs of maintaining and operating these units. This study aimed to estimate the economic costs of starting and maintaining mobile units providing harm reduction, overdose education and naloxone distribution (OEND), and medication for opioid use disorder (MOUD). Methods: As part of the HEALing Communities Study, four communities in Massachusetts (Bourne/Sandwich, Brockton, Gloucester, Salem) implemented mobile units offering OEND and MOUD (buprenorphine and naltrexone only); each selected different services tailored to their community. All provided MOUD linkage via telehealth, but only one offered in-person MOUD prescribing on the unit. We retrospectively collected detailed resource utilization data from invoices to estimate the direct economic costs from August 2020 through June 2022. Cost components were categorized into start-up and operating costs. We calculated total economic cost over the study period and the average monthly operating cost. Results: Implementing a mobile unit offering OEND and MOUD required a one-time median start-up cost of $59,762 (range: $52,062-$113,671), with 80 % of those costs attributed to the vehicle purchase. The median monthly operating cost was $14,464. The largest cost category for all mobile units was personnel costs. The monthly ongoing costs varied by community settings and services: approximately $5000 for two urban communities offering OEND and MOUD linkage via telehealth (Gloucester, Salem), $28,000 for a rural community (Bourne/Sandwich), and $23,000 for an urban community also providing in-person MOUD prescribing on the unit (Brockton). Conclusion: The economic costs of mobile substance use treatment and harm reduction units are substantial but vary by community settings and services offered. Our results provide valuable community-level economic data to stakeholders and policymakers considering establishing and/or expanding mobile units with OEND and MOUD services. Further exploration of cost-effectiveness and efficiency should be considered across different settings.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] LatinX harm reduction capital, medication for opioid use disorder, and nonfatal overdose: A structural equation model analysis among people who use drugs in Massachusetts
    Shrestha, Shikhar
    Stopka, Thomas J.
    Hughto, Jaclyn M. W.
    Case, Patricia
    Palacios, Wilson R.
    Reilly, Brittni
    Green, Traci C.
    DRUG AND ALCOHOL DEPENDENCE, 2024, 259
  • [42] Long-term patient outcomes following buprenorphine/naloxone treatment for opioid use disorder: a retrospective analysis in a commercially insured population
    Hasan, Md Mahmudul
    Noor-E-Alam, Md
    Shi, Jiesheng
    Young, Leonard D.
    Young, Gary J.
    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2022, 48 (04) : 481 - 491
  • [43] Access to medications for opioid use disorder for methamphetamine and opioid co-users between 2015-2020: a national analysis
    Ramdin, Christine
    Nelson, Lewis
    CLINICAL TOXICOLOGY, 2023, 61 : 46 - 47
  • [44] Harm Reduction Approach to Increasing Self-reported Safe Medication Storage Among Pregnant and Parenting People Receiving Opioid Use Disorder Treatment
    Grist, Elizabeth
    Thakkar, Bhushan
    Dacha, Phoebe
    Lutins, Erika
    Maxwell, Madison
    Martin, Caitlin E.
    JOURNAL OF ADDICTION MEDICINE, 2023, 17 (02) : 215 - 218
  • [45] Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial
    Socias, M. Eugenia
    Cui, Zishan
    Le Foll, Bernard
    Lei, Jingxin
    Stewart, Sherry
    Anand, Rohan
    Jutras-Aswad, Didier
    HIV MEDICINE, 2024, 25 (07) : 817 - 825
  • [46] Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial
    Socias, M. Eugenia
    Wood, Evan
    Le Foll, Bernard
    Lim, Ron
    Choi, Jin Cheol
    Mok, Wing Yin
    Bruneau, Julie
    Rehm, Juergen
    Wild, T. Cameron
    Bozinoff, Nikki
    Hassan, Ahmed
    Jutras-Aswad, Didier
    ADDICTION, 2022, 117 (10) : 2662 - 2672
  • [47] Buprenorphine-naloxone versus buprenorphine for opioid use disorder during pregnancy: A systematic review and meta-analysis
    de Lima, Fernanda Ribeiro
    Molino, Gabriela Oliveira Goncalves
    Ruelas, Mariano Gallo
    Barbosa, Eduardo Cerchi
    da Silva, Pedro Henrique Costa Matos
    Guimaraes, Felipe Bandeira de Melo
    Petrucci, Arthur Bezerra Cavalcanti
    da Silva, Giovanna Hanike Santos
    Sbardelotto, Angelo Eduardo Espindola
    Lanca, Saulo Bernardo
    Garbacka, Alicja
    DRUG AND ALCOHOL DEPENDENCE, 2025, 271
  • [48] Is there a disparity in medications for opioid use disorder based on race/ ethnicity and gender? A systematic review and meta-analysis
    Nedjat, Saharnaz
    Wang, Yun
    Eshtiaghi, Khashayar
    Fleming, Marc
    RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY, 2024, 20 (03) : 236 - 245
  • [49] Facilitators and barriers to adopting or expanding medications for opioid use disorder provision in rural Colorado jails: a qualitative analysis
    Mcneely, Heidi L.
    Schreiber, Terri L.
    Swann, William L.
    Amura, Claudia R.
    HEALTH & JUSTICE, 2024, 12 (01)
  • [50] Community Case Study of Naloxone Distribution by Hospital-Based Harm Reduction Program for People Who Use Drugs in New York City
    Riazi, Farah
    Toribio, Wilma
    Irani, Emaun
    Hughes, Terence M.
    Huxley-Reicher, Zina
    McBratney, Elisa
    Vu, Trang
    Sigel, Keith
    Weiss, Jeffrey J.
    FRONTIERS IN SOCIOLOGY, 2021, 6